CN119584954A - 眼用局部乳膏组合物 - Google Patents
眼用局部乳膏组合物 Download PDFInfo
- Publication number
- CN119584954A CN119584954A CN202380041605.2A CN202380041605A CN119584954A CN 119584954 A CN119584954 A CN 119584954A CN 202380041605 A CN202380041605 A CN 202380041605A CN 119584954 A CN119584954 A CN 119584954A
- Authority
- CN
- China
- Prior art keywords
- therapeutic composition
- ophthalmic therapeutic
- ophthalmic
- api
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263363356P | 2022-04-21 | 2022-04-21 | |
| US63/363,356 | 2022-04-21 | ||
| PCT/US2023/065956 WO2023205695A1 (en) | 2022-04-21 | 2023-04-19 | Ophthalmic topical cream compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119584954A true CN119584954A (zh) | 2025-03-07 |
Family
ID=86558713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380041605.2A Pending CN119584954A (zh) | 2022-04-21 | 2023-04-19 | 眼用局部乳膏组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12414938B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511001A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513344A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119584954A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023257375A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249922A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023205695A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026060434A1 (en) * | 2024-09-16 | 2026-03-19 | Iview Therapeutics, Inc. | Novel eyelid delivery of ophthalmic composition containing muscarinic receptor modulators for prevention and treatment of ocular disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2752008T3 (es) | 2009-10-30 | 2020-04-02 | Intratus Inc | Métodos y composiciones para la liberación sostenida de fármacos |
| US20120195969A1 (en) | 2010-09-29 | 2012-08-02 | Aidan Research And Consulting, Llc | Treatment of acne by conditioned media |
| DK2645993T3 (en) | 2010-12-03 | 2017-02-13 | Allergan Inc | Pharmaceutical cream compositions comprising oxymetazoline |
| BR112015031885A2 (pt) | 2013-06-18 | 2017-07-25 | Lubrizol Advanced Mat Inc | dispersões estáveis coloidalmente com base em galactomananas modificadas |
| CN113559105B (zh) | 2014-01-29 | 2026-06-23 | 维奥姆治疗有限公司 | 抗性痤疮的治疗 |
| US20170266289A1 (en) * | 2014-08-27 | 2017-09-21 | Abbvie Inc. | Topical formulation |
| US20170087199A1 (en) | 2016-02-10 | 2017-03-30 | Senomyx, Inc. | Compositions for delivering a cooling sensation |
| CA3032695C (en) * | 2016-08-19 | 2021-11-23 | Akrivista, LLC | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
| US11160780B2 (en) * | 2016-09-30 | 2021-11-02 | Aurobindo Pharma Ltd. | Pharmaceutical composition of ivermectin and process for preparation thereof |
| JP6946575B2 (ja) | 2018-04-24 | 2021-10-06 | アラーガン、インコーポレイテッドAllergan,Incorporated | 眼の状態の治療のためのピロカルピン塩酸塩の使用 |
| DK3870170T3 (da) * | 2018-10-26 | 2026-05-26 | Opus Genetics Inc | Behandling af presbyopi og mydriasis med fentolamin |
| WO2020141482A1 (en) * | 2019-01-04 | 2020-07-09 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising mupirocin |
| NZ781774A (en) * | 2019-03-08 | 2023-03-31 | Taro Pharma Ind | Stable topical compositions of fenoldopam |
| US20220071924A1 (en) * | 2019-03-19 | 2022-03-10 | Sol-Gel Technologies Ltd. | Treatment of ocular diseases with ophthalmic tapinarof compositions |
| WO2024026365A1 (en) | 2022-07-26 | 2024-02-01 | Glaukos Corporation | Ophthalmic topical cream formulations and uses thereof |
-
2023
- 2023-04-19 AU AU2023257375A patent/AU2023257375A1/en active Pending
- 2023-04-19 EP EP23726255.5A patent/EP4511001A1/en active Pending
- 2023-04-19 WO PCT/US2023/065956 patent/WO2023205695A1/en not_active Ceased
- 2023-04-19 JP JP2024561808A patent/JP2025513344A/ja active Pending
- 2023-04-19 CA CA3249922A patent/CA3249922A1/en active Pending
- 2023-04-19 CN CN202380041605.2A patent/CN119584954A/zh active Pending
- 2023-04-20 US US18/304,263 patent/US12414938B2/en active Active
-
2025
- 2025-08-22 US US19/307,927 patent/US20250387372A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025513344A (ja) | 2025-04-24 |
| WO2023205695A1 (en) | 2023-10-26 |
| US20230381145A1 (en) | 2023-11-30 |
| US20250387372A1 (en) | 2025-12-25 |
| EP4511001A1 (en) | 2025-02-26 |
| US12414938B2 (en) | 2025-09-16 |
| AU2023257375A1 (en) | 2024-11-07 |
| CA3249922A1 (en) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004058273A1 (en) | Use of rimexolone in the treatment of dry eye | |
| TW201105363A (en) | Eye drop for macular edema treatment | |
| JP2022537139A (ja) | 抗老眼効果を増強するためのカルバコール-ブリモニジン製剤 | |
| JP2023550632A5 (cg-RX-API-DMAC7.html) | ||
| EP0517160B1 (en) | Extended-release ophthalmic preparations | |
| US20250387372A1 (en) | Ophthalmic topical cream compositions and methods | |
| TW201815397A (zh) | 眼科用劑、眼科用藥、以及(a)羥丙基甲基纖維素及(b)維生素e類的用途 | |
| CN103977011B (zh) | 含有曲伏前列素和噻吗洛尔的眼用凝胶剂及其制备方法 | |
| JP2002212107A (ja) | 局所適用組成物 | |
| WO2015105652A1 (en) | Methods for treatment of postoperative inflammation with reduced intraocular pressure | |
| JP2025513344A5 (cg-RX-API-DMAC7.html) | ||
| CN112807275B (zh) | 一种眼用组合物及其制备方法与应用 | |
| CN102018656A (zh) | 含有效成分拉坦前列素的眼用凝胶剂及其制备方法 | |
| AU770365B2 (en) | The process for manufacturing formulation of topical beta blockers with improved efficacy | |
| TWI632913B (zh) | 用於眼部疾病或異常之組合物及其治療方法 | |
| US12527688B2 (en) | Dissolvable medical device for drugs delivery | |
| TW202033186A (zh) | 眼科用組成物 | |
| WO2017007609A1 (en) | Ocular treatment with reduced intraocular pressure | |
| AU2023255001A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| CN117598993A (zh) | 一种环孢素滴眼液及其制备方法 | |
| CN114028421A (zh) | 一种使用泊洛沙姆用于治疗眼部疾病的方法 | |
| EP4117622A1 (en) | New use and method of treatment | |
| TW202002980A (zh) | 選擇性syk抑制劑之使用方法及醫藥組合物 | |
| Mali et al. | IN SITU GEL-FORMING SYSTEMS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |